OncoMatch/Clinical Trials/NCT05521022
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Is NCT05521022 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies AT-02 for amyloidosis; systemic.
Treatment: AT-02 — This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Allowed: TTR amyloidogenic genetic variant
Genetic screening with presence of amyloid-related pathology; genetic testing confirming wild type ATTR or identification of an amyloidogenic genetic variant
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Midwest Heart and Vascular · Overland Park, Kansas
- Johns Hopkins · Baltimore, Maryland
- St. Luke's Hospital of Kansas City · Kansas City, Missouri
- Cleveland Clinic · Cleveland, Ohio
- OHSU (Oregon Health & Science University) · Portland, Oregon
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify